BioWorld Asia

Oct. 13, 2010

Synosia Therapeutics Nabs Potential $725M Pact with UCB

LONDON – Synosia Therapeutics sealed a $725 million pact on its two lead drugs for treating Parkinson's disease with UCB Pharma, and announced the closing of a third round funding of $30 million. (BioWorld International) Read More

Morphosys Pairs Antibody Platform with Sloning's

Optical Stimulation Shines New Light on Heart Muscle Cells

Ablynx Expands Merck Deal for Nanobody Technology

Diagenic Gets $12M for New Biomarker Strategy

Biotech Foundations: Biotech VC Larry Bock Uses Start-up Spirit in Science Fest

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...